Literature DB >> 7574511

Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin.

J D Knudsen1, N Frimodt-Møller, F Espersen.   

Abstract

The purpose of the study was to investigate the correlation of in vitro activity with the in vivo effect and the pharmacokinetics of penicillin in the treatment of infections with pneumococci with various susceptibilities to penicillin. We used 10 pneumococcal strains for which penicillin MICs ranged from 0.016 to 8 micrograms/ml. Time-kill curve experiments were performed with all strains. We found that the effect of penicillin in vitro is concentration independent, with a maximum effect at two to four times the MIC for penicillin-susceptible as well as penicillin-resistant pneumococci. The mouse peritonitis model with an inoculum of approximately 10(6) CFU, to which mucin was added, resulted in a reproducible lethal infection with the pneumococci. The 50% effective dose was determined for each strain, and we found a highly significant correlation between the log MIC and the log 50% effective dose of penicillin against these strains (P < 0.01). Furthermore, it was shown that the most important pharmacokinetic parameter determining the effect of penicillin in vivo was the time that the concentration of penicillin in serum was greater than the MIC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7574511      PMCID: PMC162722          DOI: 10.1128/AAC.39.6.1253

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

Review 1.  The escalating problem of antimicrobial resistance in Streptococcus pneumoniae.

Authors:  P J Chesney
Journal:  Am J Dis Child       Date:  1992-08

Review 2.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

3.  Evaluation of the E-Test for susceptibility testing of pneumococci.

Authors:  M R Jacobs; S Bajaksouzian; P C Appelbaum; A Bolmström
Journal:  Diagn Microbiol Infect Dis       Date:  1992-07       Impact factor: 2.803

4.  Qualitative susceptibility tests versus quantitative MIC tests.

Authors:  W A Craig
Journal:  Diagn Microbiol Infect Dis       Date:  1993 Mar-Apr       Impact factor: 2.803

Review 5.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

6.  Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model.

Authors:  B Fantin; J Leggett; S Ebert; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

7.  In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia.

Authors:  E Azoulay-Dupuis; E Vallee; B Veber; J P Bedos; J Bauchet; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

8.  In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.

Authors:  K T Jensen; H Schønheyder; C Pers; V F Thomsen
Journal:  APMIS       Date:  1992-06       Impact factor: 3.205

9.  Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model.

Authors:  M C Sullivan; B W Cooper; C H Nightingale; R Quintiliani; M T Lawlor
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

10.  Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae.

Authors:  R Muñoz; T J Coffey; M Daniels; C G Dowson; G Laible; J Casal; R Hakenbeck; M Jacobs; J M Musser; B G Spratt
Journal:  J Infect Dis       Date:  1991-08       Impact factor: 5.226

View more
  19 in total

1.  Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models.

Authors:  Jenny Dahl Knudsen; Inga Odenholt; Helga Erlendsdottir; Magnus Gottfredsson; Otto Cars; Niels Frimodt-Møller; Frank Espersen; Karl G Kristinsson; Sigurdur Gudmundsson
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

2.  Comparative Activity of Ceftriaxone, Ciprofloxacin, and Gentamicin as a Function of Bacterial Growth Rate Probed by Escherichia coli Chromosome Replication in the Mouse Peritonitis Model.

Authors:  Maria Schei Haugan; Anders Løbner-Olesen; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

3.  Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model.

Authors:  J D Knudsen; K Fuursted; F Espersen; N Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model.

Authors:  K Tateda; K Takashima; H Miyazaki; T Matsumoto; T Hatori; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

5.  Local epicardial inotropic drug delivery allows targeted pharmacologic intervention with preservation of myocardial loading conditions.

Authors:  Mark A Lovich; Abraham E Wei; Mikhail Y Maslov; Peter I Wu; Elazer R Edelman
Journal:  J Pharm Sci       Date:  2011-06-30       Impact factor: 3.534

6.  Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection.

Authors:  J D Knudsen; K Fuursted; S Raber; F Espersen; N Frimodt-Moller
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

7.  In vivo activity and pharmacodynamics of amoxicillin in combination with fosfomycin in fibrin clots infected with highly penicillin-resistant Streptococcus pneumoniae.

Authors:  P Chavanet; N Peyrard; A Pechinot; M Buisson; M Duong; C Neuwirth; A Kazmierczak; H Portier
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

8.  Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis.

Authors:  I Lutsar; A Ahmed; I R Friedland; M Trujillo; L Wubbel; K Olsen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

9.  Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197.

Authors:  Ivette Caro-Aguilar; Elizabeth Ottinger; Robert W Hepler; Deborah D Nahas; Chengwei Wu; Michael F Good; Michael Batzloff; Joseph G Joyce; Jon H Heinrichs; Julie M Skinner
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

10.  Estimating amoxicillin influx/efflux in chinchilla middle ear fluid and simultaneous measurement of antibacterial effect.

Authors:  Yue Huang; Zheng Yang; Linda Cartier; Belinda Cheung; Ronald J Sawchuk
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.